A virtual national laboratory for reengineering clinical translational science

Science Translational Medicine

Volumn 4, Issue 118, 2012, Pages

  Dilts, David M ^a   Rosenblum, Daniel ^b   Trochim, William M ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL LABORATORY; CLINICAL PRACTICE; CLINICAL PROTOCOL; EVIDENCE BASED MEDICINE; HEALTH CENTER; LABORATORY DIAGNOSIS; NOTE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; QUALITY CONTROL; SCIENTIFIC LITERATURE; TRANSLATIONAL RESEARCH; ARTICLE; AWARDS AND PRIZES; CLINICAL TRIAL (TOPIC); COMPUTER INTERFACE; ECONOMICS; HUMAN; LABORATORY; ORGANIZATION AND MANAGEMENT;

AWARDS AND PRIZES; CLINICAL TRIALS AS TOPIC; HUMANS; LABORATORIES; TRANSLATIONAL MEDICAL RESEARCH; USER-COMPUTER INTERFACE;

EID: 84856297479     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002951     Document Type: Note

References (22)

1. E. A. Balas, S. A. Boren, Managing Clinical Knowledge for Healthcare Improvement: Yearbook of Medical Informatics (Schattauer VerlagsgesellschaftmbH, Stuttgart, Germany, 2000).
2. K. Birmingham, What is translational research? Nat. Med. 8, 647 (2002).
3. D. G. Contopoulos-Ioannidis, G. A. Alexiou, T. C. Gouvias, J. P. A. Ioannidis, Life cycle of translational research for medical interventions. Science 321, 1298-1299 (2008).
4. J. M. Westfall, J. Mold, L. Fagnan, Practice-based research - "Blue Highways" on the NIH roadmap. JAMA 297, 403-406 (2007).
5. E. Zerhouni, The NIH roadmap. Science 302, 63-72 (2003).
6. K. I. Kaitin, Obstacles and opportunities in new drug development. Clin. Pharmacol. Ther. 83, 210-212 (2008).
7. F. S. Collins, Reengineering translational science: The time is right. Sci. Transl. Med. 3, 90cm17 (2011).
8. J. A. Dimasi, New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69, 286-296 (2001).
9. B. Munos, Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009).
10. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, A. L. Schacht, How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
11. D. M. Dilts, A. B. Sandler, Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J. Clin. Oncol. 24, 4545-4552 (2006).
12. M. Adams, D. Boike, The PDMA foundation 2004 comparative performance assessment study. Visions 28, 26-29 (2004).
13. W. Trochim, C. Kane, M. J. Graham, H. A. Pincus, Evaluating translational research: A process marker model. Clin. Transl. Sci. 4, 153-162 (2011).
14. M. A. Hamburg, Advancing regulatory science. Science 331, 987 (2011).
15. J. A. DiMasi, R. W. Hansen, H. G. Grabowski, The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
16. D. M. Dilts, S. K. Cheng, J. S. Crites, A. B. Sandler, J. H. Doroshow, Phase III clinical trial development: A process of chutes and ladders. Clin. Cancer Res. 16, 5381-5389 (2010).
17. E. L. Korn, B. Freidlin, M. Mooney, J. S. Abrams, Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J. Clin. Oncol. 28, 5197-5201 (2010).
18. S. Nass, H. Moses, J. Mendelsohn, Eds., A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (National Academic Press, Washington, DC, 2010).
19. S. K. Cheng, M. S. Dietrich, D. M. Dilts, A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin. Cancer Res. 16, 5557-5563 (2010).
20. M. L. George, J. Maxey, The Lean Six Sigma Pocket Toolbook: A Quick Reference Guide to Nearly 100 Tools for Improving Process Quality, Speed, and Complexity (McGraw-Hill Professional, New York, 2005).
21. D. Dilts, US cancer trials may go the way of the Oldsmobile. Nat. Med. 16, 632 (2010).
22. D. M. Dilts, Early warning: An ailing canary in the mine. J. Clin. Oncol. 28, 3799-3800 (2010).